Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma

Hanemaaijer, Saskia H; van Gijn, Stephanie; Oosting, Sjoukje F; Plaat, Boudewijn E C; Moek, Kirsten L; Schuuring, Ed M; van der Laan, Bernard F A M; Roodenburg, Jan L N; van Vugt, Marcel A T M; van der Vegt, Bert; Fehrmann, Rudolf S N

doi:10.5167/uzh-192527

Citations

Citation copied

Hanemaaijer, S. H., van Gijn, S., Oosting, S. F., Plaat, B. E. C., Moek, K. L., Schuuring, E. M., van der Laan, B. F. A. M., Roodenburg, J. L. N., van Vugt, M. A. T. M., van der Vegt, B., & Fehrmann, R. S. N. (2018). Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. Oral Oncology, 80, 33–39. https://doi.org/10.1016/j.oraloncology.2018.03.005

Abstract

BACKGROUND

For patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) palliative treatment options that improve overall survival are limited. The prognosis in this group remains poor and there is an unmet need for new therapeutic options. An emerging class of therapeutics, targeting tumor-specific antigens, are antibodies bound to a cytotoxic agent, known as antibody-drug conjugates (ADCs). The aim of this study was to prioritize ADC targets in HNSCC.

METHODS

With a systematic search, we identified 55 d